<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>William Harvey Research Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F4A2F754-BA46-4A85-9C14-F4BEF404040E"><gtr:id>F4A2F754-BA46-4A85-9C14-F4BEF404040E</gtr:id><gtr:firstName>Fulvio</gtr:firstName><gtr:surname>D'Acquisto</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400327"><gtr:id>5BBCF4F9-CF83-4F25-AAEC-7E3D5A91763B</gtr:id><gtr:title>A NOVEL FACET IN ANNEXIN-1 BIOLOGY: MODULATION OF THE ADAPTIVE IMMUNE RESPONSE</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400327</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>251867</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Prof. Tessa Crompton</gtr:description><gtr:id>CCBD813D-8161-4274-B8FD-460C1926E35C</gtr:id><gtr:impact>Paper in press in Cell Cycle titled &amp;quot;Role of endogenous Annexin-A1 in the regulation of thymocyte positive and negative selection&amp;quot;</gtr:impact><gtr:outcomeId>AF5FDF232C4-1</gtr:outcomeId><gtr:partnerContribution>Expertise and research support</gtr:partnerContribution><gtr:piContribution>Investigation on the role of Annexin-1 in thymocyte positive and negative selection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Society for Immunology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C82EDDB4-FC4E-419F-A77A-843EF8040651</gtr:id><gtr:impact>Invited talk for the Leucocyte Differentiation and Regulation in Disease meeting.

I have been invited to give talk to various Institute and Universities.</gtr:impact><gtr:outcomeId>07E8BCF3A25</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Life Sciences, Glasgow, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B50B07BE-F201-4C46-81A4-20BDFD19F002</gtr:id><gtr:impact>I have been selected to give an oral presentation titled &amp;quot;Annexin-1: a novel target for the therapy of autoimmune diseases&amp;quot; in the session Mechanisms and drug targets in resolution of inflammation.

I have been invited to give talk to various Institute and Universities.</gtr:impact><gtr:outcomeId>B5E7AA5E881</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>4th International Conference on Annexins 2007</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9199EB8D-D392-445B-8BA4-0535FC6D54EC</gtr:id><gtr:impact>Poster presentation.

I have been invited to give talk to various Institute and Universities.</gtr:impact><gtr:outcomeId>294EF517F35</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Summer Science Exhibitiom</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10089D48-8741-4113-A0DF-7491B8013567</gtr:id><gtr:impact>On the days of the exhibition (3rd to the 8th of July), we have engaged with more than 15,000 visitors as estimated by the number of pictures we have taken at our &amp;quot;signs of inflammation cut-out stand-in&amp;quot; (see http://www.facebook.com/SwellingPains) as well as by information we received from staff at the Royal Society (Example 3). We have distributed more than 8,000 freebies including leaflets with information about inflammation and the research activities at the College and other gadgets with the QMUL logo and details.

Visitors included students applying to University, primary school teachers and students, Science Museum staff, families and science curious from all walks of life. Last but not least, we have received very positive feedback about the whole experience and great participation from research students and staff at the WHRI (see list in Example 4) who have been very happy and proud to be part of this exciting experience.

We are currently taking this exhibit to other national and international science festival</gtr:impact><gtr:outcomeId>ANswPBvd1F1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Formyl Peptide Receptor Workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7E824B8F-058A-4611-89AF-DD5674477641</gtr:id><gtr:impact>I presented the results of a study titled: &amp;quot;The Annexin A1/FPRL-1 pathway: linking innate with adaptive immunity&amp;quot;.

I have been invited to give talk to various Institute and Universities.</gtr:impact><gtr:outcomeId>95A06D18575</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Experimental Biology, San Francisco, USA; 2006</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>174CE0D8-07DE-42DC-AB53-8578B985B14E</gtr:id><gtr:impact>I have been selected to give a presentation titled: &amp;quot;Annexin A1: a novel target of the immunosuppressive effects of Glucocorticoids in autoimmune diseases&amp;quot; in the session Innate and Acquired Immunity.

I have been invited to give talk to various Institute and Universities.</gtr:impact><gtr:outcomeId>DDAF1DAF6CA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and The London charitable foundation</gtr:description><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>E46681A4-3E63-4069-8BA3-8BCD10264056</gtr:id><gtr:outcomeId>D248FE838C60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MS Society Innovation Award</gtr:description><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>E52762EF-7943-497F-A909-B1684F1B71D7</gtr:id><gtr:outcomeId>892767985130</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and The London charitable foundation</gtr:description><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>91509637-60B4-4E20-B21C-7B3687D96CA5</gtr:id><gtr:outcomeId>686F90ABC350</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heptagon Fund</gtr:description><gtr:fundingOrg>Heptagon Fund</gtr:fundingOrg><gtr:id>5DF4722E-6291-4818-8547-499341FEDDEE</gtr:id><gtr:outcomeId>0E602C742960</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have generated neutralizing antibodies against Annexin-1 that we would like to test for their potential as immunosuppressants</gtr:description><gtr:grantRef>G0400327</gtr:grantRef><gtr:id>C4E6A132-2FF2-418C-B446-8E121C9B55F9</gtr:id><gtr:impact>Investment from privates</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>98285F56141</gtr:outcomeId><gtr:patentId>WO2010064012</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Neutralizing antibodies against Annexin-1</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We humanised the antibody against Annexin-A1 and expanding its clinical applications</gtr:description><gtr:id>40D08B04-FAB0-4E36-8F8D-D6E112516EC6</gtr:id><gtr:impact>We have shown that antibody against Annexin-A1 are powerful immunosupressive agents and unique biologic because of their 'calming effects'. This will be the first immunosuppressant with aniolytic effect</gtr:impact><gtr:outcomeId>3ACACFB6BA3</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Annexin-1 antibodies</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have generated a T cell specific Annexin-1 transgenic mouse that will be used to study the development of autoimmune diseases as well as to study the role of the immune system in regulating the emotional imbalance that is characteristic of immune disorders</gtr:description><gtr:id>CAB1D2CC-6DFB-4731-8F1B-A3EBFFD8F98A</gtr:id><gtr:impact>We believe that these mice could be used to develop novel strategies to cure autoimmune diseases and associated mental health problems.</gtr:impact><gtr:outcomeId>39B6906323E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>T cell specific Annexin-1 transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Medannex</gtr:companyName><gtr:description>This company has been established to further develop Annnexin-A1 antibodies as novel immunosuppressant.</gtr:description><gtr:id>0AD4BED5-8005-417C-98F4-A49015C689BF</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>mZfCCjbbLZn</gtr:outcomeId><gtr:url>http://medannex.org/</gtr:url><gtr:yearCompanyFormed>2008</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>79DA2DCE-2EEF-4A4E-B1BC-A28B4366ACDF</gtr:id><gtr:title>Comparative analysis of Annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets.</gtr:title><gtr:parentPublicationTitle>International immunopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6388557638819a05b0dd76fedd2fd776"><gtr:id>6388557638819a05b0dd76fedd2fd776</gtr:id><gtr:otherNames>Spurr L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1567-5769</gtr:issn><gtr:outcomeId>pm_12436_26_20974309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>719422ED-54E2-4760-A4F3-F37DDA438617</gtr:id><gtr:title>Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f50c4bcf714f7df092e3604d6c0b06a"><gtr:id>2f50c4bcf714f7df092e3604d6c0b06a</gtr:id><gtr:otherNames>Huggins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>32B779C1E8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E080036-3FCB-4773-AED8-64EC6EF03E9E</gtr:id><gtr:title>Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/464470f9987800ab81d224f26f19f16c"><gtr:id>464470f9987800ab81d224f26f19f16c</gtr:id><gtr:otherNames>Perretti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>01DFA73F1DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6123214D-0FFC-47CE-BF31-2EE5435FF7AF</gtr:id><gtr:title>On the adaptive nature of annexin-A1.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcb459050d58e98d36727c0f24490057"><gtr:id>fcb459050d58e98d36727c0f24490057</gtr:id><gtr:otherNames>D'Acquisto F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>F5C58D1B59C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE03AB2B-56E3-4213-8DBD-6416E0A5DA6A</gtr:id><gtr:title>Role of endogenous annexin-A1 in the regulation of thymocyte positive and negative selection.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d068dd410188ed39abfd72d3d6e4f604"><gtr:id>d068dd410188ed39abfd72d3d6e4f604</gtr:id><gtr:otherNames>Paschalidis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_12436_26_20139728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F658E54D-5FCD-43C0-B359-4B11E20A9F7E</gtr:id><gtr:title>Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcb459050d58e98d36727c0f24490057"><gtr:id>fcb459050d58e98d36727c0f24490057</gtr:id><gtr:otherNames>D'Acquisto F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>F60DDDD4ECF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>594EECBE-9C4F-42BE-B0A7-B4C3F8E78624</gtr:id><gtr:title>Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9331e1caa3d6f88b638e84b19e237c00"><gtr:id>9331e1caa3d6f88b638e84b19e237c00</gtr:id><gtr:otherNames>Vong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>E26B2E27899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08D1577A-4AF1-4F95-ABF4-F73A9846B283</gtr:id><gtr:title>Annexin-A1: a pivotal regulator of the innate and adaptive immune systems.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcb459050d58e98d36727c0f24490057"><gtr:id>fcb459050d58e98d36727c0f24490057</gtr:id><gtr:otherNames>D'Acquisto F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>9F3C59D6187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A94A098-4A6E-48E3-BD76-B2C3206F583C</gtr:id><gtr:title>Modulation of experimental autoimmune encephalomyelitis by endogenous annexin A1.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d068dd410188ed39abfd72d3d6e4f604"><gtr:id>d068dd410188ed39abfd72d3d6e4f604</gtr:id><gtr:otherNames>Paschalidis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn><gtr:outcomeId>E0189E6A403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F9B9C59-436E-446E-A245-DF9B176EEC45</gtr:id><gtr:title>Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcb459050d58e98d36727c0f24490057"><gtr:id>fcb459050d58e98d36727c0f24490057</gtr:id><gtr:otherNames>D'Acquisto F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>E5D5BA9DB3A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE733313-DE8A-4C91-93CA-BB3A45B5B54F</gtr:id><gtr:title>Annexin-1 modulates T-cell activation and differentiation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcb459050d58e98d36727c0f24490057"><gtr:id>fcb459050d58e98d36727c0f24490057</gtr:id><gtr:otherNames>D'Acquisto F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>F4172856DFD</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400327</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>